Clinical trials: House Dust Mite Rhinitis
House Dust Mite Allergy
SUBLIVAC FIX Mite Mixture Dose Tolerability Study
Allergic rhinitis/rhinoconjunctivitis is a symptomatic disorder of the nose induced by an immunoglobulin E (IgE) mediated inflammatory response. Treatment may involve pharmacotherapy and specific immunotherapy (IT).
- Trial name
- DTS (NCT02345278)
- Testing
- SUBLIVAC FIX Mite mixture
- Where
- 10 sites in Germany
- Volunteers
- 81 people
- Sponsor
- HAL Allergy
Perennial Allergic Rhinitis, Rhinitis, Allergic
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explored the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers.
- Trial name
- NCT05122143
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Altamira Medica Ltd.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
- Trial name
- NCT01438463
- Testing
- PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml, PURETHAL Mites 50,000 AU/ml
- Where
- 35 sites in Austria, Belgium and 3 more
- Volunteers
- 290 people
- Sponsor
- HAL Allergy
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting
- Trial name
- NCT00574704
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Volunteers
- 40 people
- Sponsor
- Cytos Biotechnology AG
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09.
- Trial name
- Oraltek-58 (NCT07348302)
- Testing
- Allergen Immunotherapy Extract
- Where
- 19 sites in Argentina, China and 2 more
- Volunteers
- 736 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
The objective of this clinical trial is to assess the safety and efficacy of sublingual application of allergen extracts for specific immunotherapy in patients suffering from perennial allergic rhinitis due to house dust mites.
- Trial name
- NCT01014325
- Testing
- Allergen extract
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Roxall Medizin
Allergic Rhinoconjunctivitis, Allergic Rhinitis
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
- Trial name
- NCT07060885
- Testing
- HDM SLIT-tablet (12 SQ-HDM)
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Adolescent Mite Allergy Safety Evaluation
This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.
- Trial name
- AMASE (NCT04541004)
- Testing
- HDM SLIT-tablet
- Where
- 27 sites in Czechia, Germany and 1 more
- Volunteers
- 253 people
- Sponsor
- ALK-Abelló A/S
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
Mite Asthma Pediatric Immunotherapy Trial
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma…
- Conditions
- Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MAPIT (NCT03654976)
- Testing
- HDM SLIT-tablet
- Where
- 64 sites in United States, Bulgaria and 7 more
- Volunteers
- 533 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
House Dust Mite Allergy Trial In Children
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
- Conditions
- Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MATIC (NCT04145219)
- Testing
- Sublingual allergy immunotherapy tablet
- Where
- 113 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,460 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.
- Trial name
- NCT01700192
- Testing
- MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets
- Volunteers
- 1,482 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy
The primary objective of the trial is to evaluate the dose-response relationship with regards to change in immunological parameters and safety for SLITone ULTRA house dust mite mix in adult subjects with moderate to severe HDM…
- Trial name
- SUMMIT (NCT01728298)
- Testing
- SLITone ULTRA HDM immunotherapy
- Where
- France
- Volunteers
- 219 people
- Sponsor
- ALK-Abelló A/S
Mite Allergy, Rhinitis, Allergic
Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
When administering clinical trial drugs to patients with house dust mite allergic rhinitis, safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement and immune activity of the disease are…
- Conditions
- Mite Allergy, Rhinitis, Allergic, House Dust Mite Rhinitis
- Trial name
- NCT05525650
- Testing
- House Dust Mite Extract, Dermatophagoides Farinae
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- RAPHAS
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12…
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
- Trial name
- CARIOCA (NCT03746860)
- Testing
- Tablet, Dispersible
- Where
- France
- Volunteers
- 1,508 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to Dust Mite
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
The purpose of this study is to assess the efficacy of one dose of sublingual immunotherapy (SLIT) administered to children and adolescents as allergen-based tablets once daily over a period of 24 months over 3 years compared to…
- Trial name
- NCT01199133
- Testing
- 300 IR house dust mites allergen extract tablet
- Volunteers
- 471 people
- Sponsor
- Stallergenes Greer
Allergy, Asthma
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with ALK HDM tablets given once daily over 60…
- Conditions
- Allergy, Asthma, Rhinitis
- Trial name
- NCT02596321
- Testing
- Mitizax
- Where
- 9 sites in Belarus, Russia
- Volunteers
- 112 people
- Sponsor
- Abbott
Allergic Rhinitis
Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites
The objective of this study is to evaluate the efficacy and safety of specific subcutaneous immunotherapy with modified allergen extracts.
- Trial name
- NCT01013116
- Testing
- modified allergen extract of house dust mites
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Roxall Medizin
House Dust Mite Allergy
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
The trial is performed to assess efficacy and safety of Beltavac with polymerized extract of house dust mites in allergic Rhinoconjunctivitis associated or not with asthma
- Trial name
- PROACAROS (NCT05395689)
- Testing
- House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae
- Where
- 18 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Probelte Pharma S.L.U.